US equities
|
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Frequency Therapeutics, Inc.
Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results
August 10, 2023
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results
May 12, 2023
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results
March 10, 2023
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics to Participate at Upcoming March Investor Conferences
February 27, 2023
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
February 13, 2023
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss
December 15, 2022
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results
November 17, 2022
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results
November 08, 2022
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
October 12, 2022
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics to Participate in September Investor and Medical Conferences
August 30, 2022
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results
August 09, 2022
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference
May 18, 2022
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results
May 04, 2022
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics to Participate in B. Riley Securities’ Neuro & Ophthalmology Investor Conference
April 22, 2022
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results
March 15, 2022
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences
February 28, 2022
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise
December 09, 2021
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results
November 15, 2021
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis
November 09, 2021
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program
October 27, 2021
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint
October 21, 2021
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points
September 22, 2021
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics to Present at Upcoming Investor Conferences
September 08, 2021
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results
August 12, 2021
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics to Present at Upcoming Jefferies and Goldman Sachs Healthcare Investor Conferences
May 25, 2021
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics Provides Statement of Support for the Hearing Loss Association of America’s Externally-Led Patient-Focused Drug Development Meeting to Address Sensorineural Hearing Loss
May 20, 2021
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics Provides Business Updates and Reports First Quarter 2021 Financial Results
May 13, 2021
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics Expands its Clinical Development Team, Adding Expertise in Inner Ear Physiology and Translational Science
April 13, 2021
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
Frequency Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
April 09, 2021
From
Frequency Therapeutics, Inc.
Via
Business Wire
Tickers
FREQ
